collection
MENU ▼
Read by QxMD icon Read
search

Diabetes

shared collection
54 papers 0 to 25 followers Related to managing patients with diabetes
By Michael Kelly Assistant Professor
https://www.readbyqxmd.com/read/28289041/coadministration-of-canagliflozin-and-phentermine-for-weight-management-in-overweight-and-obese-individuals-without-diabetes-a-randomized-clinical-trial
#1
Priscilla Hollander, Harold E Bays, Julio Rosenstock, Mary Ellen Frustaci, Albert Fung, Frank Vercruysse, Ngozi Erondu
OBJECTIVE: To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, phase 2a, randomized, double-blind, PBO-controlled, multicenter, parallel-group study enrolled individuals who were obese or overweight without type 2 diabetes (N = 335, age 18-65 years, BMI ≥30 to <50 kg/m(2) or BMI ≥27 to <50 kg/m(2) with hypertension and/or dyslipidemia)...
March 13, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28288484/pharmacologic-therapy-for-type-2-diabetes-synopsis-of-the-2017-american-diabetes-association-standards-of-medical-care-in-diabetes
#2
James J Chamberlain, William H Herman, Sandra Leal, Andrew S Rhinehart, Jay H Shubrook, Neil Skolnik, Rita Rastogi Kalyani
Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence...
March 14, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28283564/incidence-of-ketoacidosis-in-the-danish-type-2-diabetes-population-before-and-after-introduction-of-sodium-glucose-cotransporter-2-inhibitors-a-nationwide-retrospective-cohort-study-1995-2014
#3
LETTER
Majken Linnemann Jensen, Frederik Persson, Gregers S Andersen, Martin Ridderstråle, John J Nolan, Bendix Carstensen, Marit E Jørgensen
No abstract text is available yet for this article.
March 10, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28231831/a-randomised-study-of-the-impact-of-the-sglt2-inhibitor-dapagliflozin-on-microvascular-and-macrovascular-circulation
#4
Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V Karg, Peter Bramlage, Roland E Schmieder
BACKGROUND: The sodium-glucose cotransporter 2 inhibitor, dapagliflozin, has been shown to improve diabetic control and reduce blood pressure in patients with type 2 diabetes mellitus. Its effects on micro- and macrovascular structure and function have not yet been reported. METHODS: This was a prospective, single-centre, placebo-controlled, double-blind, randomised crossover phase IIIb study conducted between March 2014 and February 2015. After a 4-week run-in/washout phase, patients (N = 59) received 6 weeks of either dapagliflozin 10 mg or placebo once daily...
February 23, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28223297/efficacy-and-safety-of-metreleptin-therapy-in-patients-with-type-1-diabetes-a-pilot-study
#5
Chandna Vasandani, Gregory O Clark, Beverley Adams-Huet, Claudia Quittner, Abhimanyu Garg
OBJECTIVE: To study the efficacy and safety of metreleptin therapy in patients with suboptimally controlled type 1 diabetes mellitus (T1DM). RESEARCH DESIGN AND METHODS: After a baseline period of 4 weeks, five female and three male patients with T1DM (mean age 33 years, BMI 23.8 kg/m(2)) received metreleptin (0.08 mg/kg/day in females and 0.04 mg/kg/day in males) subcutaneously twice daily for 20 weeks followed by an off-therapy period of 4 weeks. RESULTS: Metreleptin therapy did not lower hemoglobin A1c significantly compared with the baseline value (mean difference -0...
February 21, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28222461/elements-for-success-in-managing-type-2-diabetes-with-sglt-2-inhibitors-individualizing-treatment-with-sglt-2-inhibitor-therapy-in-type-2-diabetes-mellitus
#6
Eden M Miller
The largely self-managed nature of type 2 diabetes mellitus (T2DM) underscores the importance of a collaborative decision-making process between patient and provider that best aligns the medication characteristics with the needs, interests, and abilities of the patient and with the treatment goals. The treatment regimen should be kept as simple as possible. This article applies these general principles to the use of sodium glucose cotransporter-2 inhibitor (SGLT-2) therapy, based on evidence from published studies and the clinical experience of the author...
February 2017: Journal of Family Practice
https://www.readbyqxmd.com/read/28209654/replace-bg-a-randomized-trial-comparing-continuous-glucose-monitoring-with-and-without-routine-blood-glucose-monitoring-in-adults-with-well-controlled-type-1-diabetes
#7
Grazia Aleppo, Katrina J Ruedy, Tonya D Riddlesworth, Davida F Kruger, Anne L Peters, Irl Hirsch, Richard M Bergenstal, Elena Toschi, Andrew J Ahmann, Viral N Shah, Michael R Rickels, Bruce W Bode, Athena Philis-Tsimikas, Rodica Pop-Busui, Henry Rodriguez, Emily Eyth, Anuj Bhargava, Craig Kollman, Roy W Beck
OBJECTIVE: To determine whether the use of continuous glucose monitoring (CGM) without confirmatory blood glucose monitoring (BGM) measurements is as safe and effective as using CGM adjunctive to BGM in adults with well-controlled type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: A randomized noninferiority clinical trial was conducted at 14 sites in the T1D Exchange Clinic Network. Participants were ≥18 years of age (mean 44 ± 14 years), had T1D for ≥1 year (mean duration 24 ± 12 years), used an insulin pump, and had an HbA1c ≤9...
April 2017: Diabetes Care
https://www.readbyqxmd.com/read/28188240/lixisenatide-therapy-in-older-patients-with-type-2-diabetes-inadequately-controlled-on-their-current-antidiabetic-treatment-the-getgoal-o-randomized-trial
#8
Graydon S Meneilly, Christine Roy-Duval, Hasan Alawi, George Dailey, Diego Bellido, Carlos Trescoli, Helard Manrique Hurtado, Hailing Guo, Valerie Pilorget, Riccardo Perfetti, Hamish Simpson
OBJECTIVE: To evaluate the efficacy and safety of lixisenatide versus placebo on glycemic control in older patients with type 2 diabetes uncontrolled on their current antidiabetic treatment. RESEARCH DESIGN AND METHODS: In this phase III, double-blind, randomized, placebo-controlled, two-arm, parallel-group, multicenter trial, patients aged ≥70 years were randomized to receive once-daily lixisenatide 20 μg or placebo before breakfast concomitantly with their existing antidiabetic therapy (including insulin) for 24 weeks...
February 10, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28186933/use-of-the-diabetes-medication-choice-decision-aid-in-patients-with-type-2-diabetes-in-greece-a-cluster-randomised-trial
#9
Thomas Karagiannis, Aris Liakos, Megan E Branda, Eleni Athanasiadou, Maria Mainou, Panagiota Boura, Dimitrios G Goulis, Annie LeBlanc, Victor M Montori, Apostolos Tsapas
OBJECTIVE: To assess the efficacy of the Diabetes Medication Choice Decision Aid among patients with type 2 diabetes in Greece. DESIGN: Open-label cluster randomised controlled trial. SETTING: Primary and secondary care practices across Greece. PARTICIPANTS: 5 sites allocated to the decision aid (n=101 patients) and 4 sites to control (n=103 patients). INTERVENTION: Clinicians and patients in the intervention arm used a decision aid, based on outcomes that both consider important when choosing among antihyperglycaemic medications...
November 14, 2016: BMJ Open
https://www.readbyqxmd.com/read/27884312/management-of-patients-with-diabetes-and-ckd-%C3%A2-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference
#10
Vlado Perkovic, Rajiv Agarwal, Paola Fioretto, Brenda R Hemmelgarn, Adeera Levin, Merlin C Thomas, Christoph Wanner, Bertram L Kasiske, David C Wheeler, Per-Henrik Groop
The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development...
December 2016: Kidney International
https://www.readbyqxmd.com/read/28164074/clinical-features-of-childhood-diabetes-mellitus-focusing-on-latent-autoimmune-diabetes
#11
Seung Ho Lee, Jeesuk Yu
PURPOSE: This study was designed to evaluate the clinical characteristics of childhood diabetes mellitus (DM) according to its classification as well as the clinical course of latent autoimmune diabetes (LAD) that initially showed noninsulin dependence despite autoantibody positivity. METHODS: A total of 91 subjects diagnosed between 2001 and 2015 were enrolled in the study. They were classified into 3 groups: type 1 DM, LAD, and type 2 DM. Clinical features and laboratory findings were compared among groups...
December 2016: Annals of Pediatric Endocrinology & Metabolism
https://www.readbyqxmd.com/read/28133970/lixisenatide
#12
Delilah McCarty, Megan Coleman, Cassie L Boland
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of the glucagon-like peptide-1 receptor agonist (GLP-1RA), lixisenatide, in the treatment of type 2 diabetes mellitus. DATA SOURCES: A PubMed (1966-2016) search was conducted using the following keywords: lixisenatide, AVE0010, glucagon-like peptide-1 agonist, and type 2 diabetes. References were reviewed to identify additional sources. STUDY SELECTION AND DATA EXTRACTION: Articles written in English were included if they evaluated the pharmacology, pharmacokinetics, efficacy, or safety of lixisenatide in human subjects...
January 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28129251/effects-of-the-glucagon-like-peptide-1-receptor-agonist-liraglutide-on-24-h-ambulatory-blood-pressure-in-patients-with-type-2-diabetes-and-stable-coronary-artery-disease-a-randomized-double-blind-placebo-controlled-crossover-study
#13
Preman Kumarathurai, Christian Anholm, Andreas Fabricius-Bjerre, Olav W Nielsen, Ole Kristiansen, Sten Madsbad, Steen B Haugaard, Ahmad Sajadieh
OBJECTIVE: The glucagon-like peptide-1 receptor agonist liraglutide has been shown to reduce blood pressure (BP) in clinical trials using office BP measurements. However, the effects of liraglutide on 24-h BP and on the diurnal variation in BP have not been explored sufficiently. METHODS: Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study...
January 27, 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28115474/comparison-of-insulin-glargine-300-units-ml-and-100-units-ml-in-adults-with-type-1-diabetes-continuous-glucose-monitoring-profiles-and-variability-using-morning-or-evening-injections
#14
Richard M Bergenstal, Timothy S Bailey, David Rodbard, Monika Ziemen, Hailing Guo, Isabel Muehlen-Bartmer, Andrew J Ahmann
OBJECTIVE: The objective of this study was to compare glucose control in participants with type 1 diabetes receiving insulin glargine 300 units/mL (Gla-300) or glargine 100 units/mL (Gla-100) in the morning or evening, in combination with mealtime insulin. RESEARCH DESIGN AND METHODS: In this 16-week, exploratory, open-label, parallel-group, two-period crossover study (clinicaltrials.gov identifier NCT01658579), 59 adults with type 1 diabetes were randomized (1:1:1:1) to once-daily Gla-300 or Gla-100 given in the morning or evening (with crossover in the injection schedule)...
April 2017: Diabetes Care
https://www.readbyqxmd.com/read/28114680/association-of-patient-physician-language-concordance-and-glycemic-control-for-limited-english-proficiency-latinos-with-type-2-diabetes
#15
Melissa M Parker, Alicia Fernández, Howard H Moffet, Richard W Grant, Antonia Torreblanca, Andrew J Karter
Importance: Providing culturally competent care to the growing number of limited-English proficiency (LEP) Latinos with diabetes in the United States is challenging. Objective: To evaluate changes in risk factor control among LEP Latinos with diabetes who switched from language-discordant (English-only) primary care physicians (PCPs) to language-concordant (Spanish-speaking) PCPs or vice versa. Design, Setting, and Participants: This pre-post, difference-in-differences study selected 1605 adult patients with diabetes who self-identified as Latino, whose preferred language was Spanish, and who switched PCPs between January 1, 2007, and December 31, 2013...
March 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28075100/ada-updates-standards-of-medical-care-for-patients-with-diabetes-mellitus
#16
Carrie Armstrong
No abstract text is available yet for this article.
January 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/28057693/assessing-the-safety-of-sitagliptin-in-older-participants-in-the-trial-evaluating-cardiovascular-outcomes-with-sitagliptin-tecos
#17
M Angelyn Bethel, Samuel S Engel, Jennifer B Green, Zhen Huang, Robert G Josse, Keith D Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren K McGuire, Eric D Peterson, Rury R Holman
OBJECTIVE: Limited data exist regarding safety and efficacy of antihyperglycemic drugs in older patients with type 2 diabetes. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was a randomized, double-blind, placebo-controlled trial assessing the impact of sitagliptin on a primary composite outcome of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or unstable angina hospitalizations in patients with type 2 diabetes (HbA1c ≥6.5% [48 mmol/mol] and ≤8...
January 5, 2017: Diabetes Care
https://www.readbyqxmd.com/read/27999003/diabetic-neuropathy-a-position-statement-by-the-american-diabetes-association
#18
REVIEW
Rodica Pop-Busui, Andrew J M Boulton, Eva L Feldman, Vera Bril, Roy Freeman, Rayaz A Malik, Jay M Sosenko, Dan Ziegler
No abstract text is available yet for this article.
January 2017: Diabetes Care
https://www.readbyqxmd.com/read/27998910/pancreatic-effects-of-liraglutide-or-sitagliptin-in-overweight-patients-with-type-2-diabetes-a-12-week-randomized-placebo-controlled-trial
#19
Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Mark H H Kramer, Indra C Pieters-van den Bos, Karuna E W Vendrik, Trynke Hoekstra, Marco J Bruno, Michaela Diamant, Daniël H van Raalte, Djuna L Cahen
OBJECTIVE: To assess the mechanistic effects of the glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide and the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin on (exocrine) pancreatic physiology and morphology. RESEARCH DESIGN AND METHODS: For this randomized, double-blind, parallel-group trial, 55 patients with type 2 diabetes treated with metformin and/or sulfonylurea agents were included. Participants received liraglutide 1.8 mg (n = 19), sitagliptin 100 mg (n = 19), or matching placebos (n = 17) once daily for 12 weeks...
March 2017: Diabetes Care
https://www.readbyqxmd.com/read/27835680/benefits-and-harms-of-sodium-glucose-co-transporter-2-inhibitors-in-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis
#20
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll
OBJECTIVE: Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes. DESIGN: Systematic review and meta-analysis. DATA SOURCES AND STUDY SELECTION: We included double-blinded, randomised controlled trials (RCTs) evaluating SGLT2-i administered in the highest approved therapeutic doses (canagliflozin 300 mg/day, dapagliflozin 10 mg/day, and empagliflozin 25 mg/day) for ≥12 weeks...
2016: PloS One
label_collection
label_collection
7141
1
2
2016-12-13 17:03:38
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"